Nab-Paclitaxel Shows Greater Benefit Than Paclitaxel in Breast Cancer Subsets

According to results from the GeparSepto Trial, nab-paclitaxel proves to be more beneficial than paclitaxel in certain subsets of breast cancer. In particular, in patients with triple-negative breast cancer nab-paclitaxel showed almost a doubling of the PCR rate compared with paclitaxel.

 Targeted Oncology